This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-23 and is reviewed periodically as new material appears.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
At the time of Exubera's discontinuation, several other companies were pursuing inhaled insulin including Alkermes working with Eli Lilly and Company, MannKind Corporation, and Aradigm working with Novo Nordisk. By March 2008, except for MannKind's Afrezza product, all of these products had been discontinued because investors all decided to withdraw funding. On March 16, 2009, MannKind submitted a new drug application for their inhalable insulin. In 2011, the FDA denied approval of Afrezza; because the design of the delivery device had changed, it requested additional clinical trials to ensure that people would use it the same way as the earlier versions. After conducting further studies, Mannkind submitted a new application, and in June 2014, the FDA approved Afrezza for both type 1 and type 2 adult diabetics, with a label restriction for patients having asthma, active lung cancer, or COPD. In 2014, Mannkind and Sanofi agreed that Sanofi would take over manufacturing and marketing of Afrezza, but Sanofi said it was dropping the effort in January 2016 due to poor sales of US$7.5 million in 2015; the companies formally terminated the agreement in November 2016. At the time that Sanofi announced it was dropping the product Mannkind said it would continue alone, and it had taken over manufacturing and relaunched the drug by July 2016.
== Metabolism/Biotransformation == Quisqualic acid enters the body through different routes, such as ingestion, inhalation, or injection. The ADME (absorption, distribution, metabolism and excretion) process has been studied by means of various animal models in the laboratory. Absorption: quisqualic acid is a small and lipophilic molecule, thus is expected to be rapid. It is predicted to be absorbed in the human intestine and from then it circulates to the blood brain barrier. Analysis of amino acid transport systems is complex by the presence of multiple transporters with overlapping specificity. Since glutamate and quisqualic acid are similar, it is predicted that sodium/potassium transport in the gastrointestinal tract is the absorption site of the acid. Distribution: knowing the receptors it binds to, it can be readily predicted where the acid is present such as: hippocampus, basal ganglia, olfactory regions. Metabolism: quisqualic acid is thought to be metabolized in the liver by oxidative metabolism carried out by cytochrome P450 enzymes, Glutathione S-transferase (detoxifying agents). A study showed that the exposure to quisqualic acid revealed that P450, GST were involved. It is also confirmed by using admetSAR tool to evaluate chemical ADMET properties. Its metabolites are thought to be NMDA and quinolinic acid. Excretion: Mostly, as a rule of thumb, amino acids undergo transamination/deamination in the liver. Thus amino acids are converted into ammonia and keto acids, which are eventually excreted via the kidneys.
In Australia, ketamine is listed as a Schedule 8 controlled drug under the Poisons Standard (October 2015). In Canada, ketamine has been classified as a Schedule I narcotic since 2005. In December 2013, the government of India, in response to rising recreational use and the use of ketamine as a date rape drug, added it to Schedule X of the Drug and Cosmetics Act, requiring a special license for sale and maintenance of records of all sales for two years. In the United Kingdom, it was labeled a Class B drug on 12 February 2014. In 2025, the Home Office requested a review of the classification with a view to changing it to Class A, based on an increase in recreational use and the negative health consequences. The increase in recreational use prompted ketamine to be placed in Schedule III of the United States Controlled Substances Act in August 1999.
Gastrin–cholecystokinin family: gastrin and cholecystokinin Secretin family: secretin, glucagon, vasoactive intestinal peptide and gastric inhibitory peptide Somatostatin family Motilin family Substance P. Ghrelin is a peptide hormone released from the stomach and liver and is often referred to as the "hunger hormone" since high levels of it are found in individuals that are fasting. Ghrelin agonistic treatments can be used to treat illnesses such as anorexia and loss of appetites in cancer patients. Ghrelin treatments for obesity are still under intense scrutiny and no conclusive evidence has been reached. This hormone stimulates growth hormone release. Amylin controls glucose homeostasis and gastric motility Glucose-dependent insulinotropic polypeptide possesses an acute influence on food intake through its effects on adipocytes Oxyntomodulin plays a role in controlling acid secretion and satiation
==== Impact on growers ==== The US-supported coca eradication policy has been criticized for its negative impact on the livelihood of South American coca growers, in a region where the coca leaf has traditionally been chewed and used in tea and for religious, medicinal and nutritional purposes by locals Making traditional coca cultivation illegal is viewed as unjust. In areas where forced eradication also destroyed other food or market crops, without providing an alternative, farmers were left starving and destitute.
Sources: en.wikipedia.org
== Therapeutic use and drug development == Opinions regarding the use of ANP for the treatment of acute heart failure and kidney disease are varied. While this molecule has been shown to successfully restore some hemodynamic parameters following heart failure, and yield clinical improvement for kidney injury, whether it ultimately reduces mortality and its long-term effects are unknown. Therefore, more studies need to be conducted to better understand the therapeutic effects of ANP. Newly synthesized homologues of ANP molecule are being assessed for the treatment of acute heart failure. Preliminary research on one of such molecules, ularitide, has shown that this drug is safe, well tolerated, and effective in the treatment of acute heart failure.
== Prognosis == A 2014 study classified cases into three types—EBS, JEB and DEB—and reviewed their times of death. The first two types tended to die in infancy and the last in early adulthood. In a survey of 11 families affected by the disease, lack of awareness of the disease by both the public and health care providers raised concerns about the care provided.
=== Psychotherapy === Ibogaine was used as an adjunct to psychotherapy by Claudio Naranjo, documented in his 1973 book The Healing Journey: New Approaches to Consciousness. He was awarded patent in 1974.
From 1850 the first sanatoriums were founded and treatments were oriented along systematic, medical-scientific lines, however, the importance of kumyss treatment of tuberculosis in Russia lasted until about 1970, then it was gradually replaced by modern medicine. However, Kumys' treatment was the most effective tuberculosis therapy for many years. Treatment with kumyss & mare's milk has been extended to many other diseases in Russia and Kazakhstan over the decades. Language barriers and cultural differences still prevent exchange between the Western cultural area and these cultures today, however, Russia and Kazakhstan are still conducting scientific research on the effects of equine milk and kumyss on humans. Postnikov, a Russian doctor who dedicated his career to the research and use of horse milk in the mid-19th century, summed up its effects in three words:
"If the prepotency of Peru, if its population and resources were worth, as Santa Cruz has claimed, to justify its policy, the government in charge of Foreign Relations of the Argentine Confederation would seize them to justify the war against the Peruvian Confederation. -Bolivian (...) if there was no balance between Peru and Bolivia, will it exist between the United States and the Argentine Confederation? (...) that fusion under the aegis of a conqueror is dangerous and the propensity of Peru to aggrandize it does not promise Bolivia neither security nor rest."
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.